Compounds > 1-(5-isoquinolinesulfonyl)-2-methylpiperazine
Page last updated: 2024-10-28

1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Dyskinesia, Medication-Induced

1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Dyskinesia, Medication-Induced in 1 studies

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Lopez-Lopez, A1
Labandeira, CM1
Labandeira-Garcia, JL1
Muñoz, A1

Other Studies

1 other study available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Dyskinesia, Medication-Induced

ArticleYear
Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    British journal of pharmacology, 2020, Volume: 177, Issue:24

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Dyskinesia, Drug-Ind

2020